Product image of Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic) supplied by GNH India

Influvac

Active Ingredient:
Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic
Origin:
EU

Influvac (Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic)

Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26) and Influenza A/Vic, the active ingredient in Influvac, is a vaccine presented as an injectable solution for intramuscular and subcutaneous use. It induces immunity against seasonal influenza in individuals recommended for vaccination.

GNH India supplies Influvac as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Viatris Healthcare Limited

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Influvac is a vaccine that targets the influenza virus family to prevent infection and its complications.

  • Seasonal influenza: reduces the incidence of flu caused by circulating influenza A and B strains.
  • High‑risk populations (elderly, chronic disease patients): lowers the risk of severe disease and related complications.
  • Healthcare workers: helps prevent transmission of influenza in clinical settings.

How It Works

  • Influvac contains inactivated influenza virus strains (B/Austria/2021‑like and A/Vic) that are administered intramuscularly or subcutaneously. The viral antigens are recognized by the immune system, prompting B‑cell activation and production of strain‑specific antibodies, as well as T‑cell responses, thereby establishing active immunity that can neutralize future exposure to the matched influenza viruses.

Side Effects

Common Side Effects

  • Injection site pain: mild to moderate discomfort at the injection site.
  • Redness or swelling: localized erythema or edema.
  • Low‑grade fever: transient temperature rise up to 38°C.
  • Headache or muscle aches: mild systemic symptoms.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Guillain‑Barré syndrome: rare neurological disorder with progressive weakness.
  • High fever or seizures: uncommon but potentially serious systemic reactions.

Precautions & Warnings

Influvac should be administered with consideration of the following precautions.

  • Assess allergy history: avoid in individuals with severe egg allergy or known vaccine component hypersensitivity.
  • Post‑vaccination observation: monitor the recipient for at least 15 minutes for immediate reactions.
  • Delay vaccination if acute febrile illness is present: postpone until recovery.
  • Avoid concurrent administration of live vaccines: separate by at least 4 weeks.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Influvac may interact with other agents that affect immune response.

Major Interactions (Avoid)

  • Live attenuated vaccines: may interfere with immune response to either product.
  • Immunoglobulin therapy: can reduce vaccine efficacy.
  • Immunosuppressive therapy: may diminish antibody production.

Moderate Interactions (Monitor Closely)

  • Antipyretics (acetaminophen, ibuprofen): may mask fever after vaccination.
  • Antihistamines: may lessen local reaction but do not affect overall immunity.

Frequently Asked Questions

Influvac is an injectable influenza vaccine indicated for the prevention of seasonal influenza. It contains inactivated strains of influenza B (Austria/2021‑like) and influenza A (Victoria) to stimulate protective immunity in individuals who receive the vaccine.

The active ingredients are inactivated virus particles that present the immune system with the specific antigens of influenza B/Austria and influenza A/Vic. This exposure triggers the body to produce strain‑specific antibodies and cellular immunity, preparing the immune system to neutralize the live virus if encountered later.

The dosage and administration schedule for Influvac are determined by the prescribing healthcare professional based on local immunization guidelines, the age of the recipient, and any relevant medical considerations. No fixed regimen is provided here.

The safety of Influvac in pregnancy or while breastfeeding has not been definitively established. Healthcare providers should weigh the potential benefits of influenza protection against any uncertain risks and follow national recommendations for vaccinating pregnant or lactating individuals.

To request Influvac, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and necessary import documentation.

Influvac is a split‑virus, inactivated influenza vaccine containing the same WHO‑recommended B and A strains as many other seasonal flu vaccines. Compared with live‑attenuated nasal sprays, Influvac is administered by injection and is suitable for a broader range of age groups, including those with contraindications to live vaccines.

Influvac must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must never be frozen or shaken. Prior to administration, allow the vial to reach room temperature if required by the label.

Influvac is given by a single intramuscular or subcutaneous injection, typically into the deltoid muscle of the upper arm. The exact route and site are chosen by the healthcare professional based on patient age, muscle mass and clinical guidelines.

The most serious risks include severe allergic reactions such as anaphylaxis, and rare neurological events like Guillain‑Barré syndrome. Recipients should be observed for at least 15 minutes after injection, and any signs of a serious reaction should be treated promptly.

Individuals with a known severe allergy to any component of the vaccine, including egg proteins when present, or those who have experienced a previous severe reaction to an influenza vaccine, should not receive Influvac. Consultation with a healthcare provider is essential for anyone with contraindications.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Influenza Virus B/Austria/1359417/2021-Like Strain (B/Austria/1359417/2021, Bvr-26), Influenza A/Vic

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT